In Brief NK cells defend against various pathogens and tumors, but the mechanisms by which they control tumor metastases are not clear. Here, Glasner et al. show that NK cells prevent tumor metastases in vivo by editing tumor architecture via NKp46-mediated IFN-g production that leads to upregulation of extracellular matrix protein FN1 in the tumor.
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SUMMARY
Natural killer (NK) cells are innate lymphoid cells, and their presence within human tumors correlates with better prognosis. However, the mechanisms by which NK cells control tumors in vivo are unclear. Here, we used reflectance confocal microscopy (RCM) imaging in humans and in mice to visualize tumor architecture in vivo. We demonstrated that signaling via the NK cell receptor NKp46 (human) and Ncr1 (mouse) induced interferon-g (IFN-g) secretion from intratumoral NK cells. NKp46-and Ncr1-mediated IFN-g production led to the increased expression of the extracellular matrix protein fibronectin 1 (FN1) in the tumors, which altered primary tumor architecture and resulted in decreased metastases formation. Injection of IFN-g into tumor-bearing mice or transgenic overexpression of Ncr1 in NK cells in mice resulted in decreased metastasis formation. Thus, we have defined a mechanism of NK cell-mediated control of metastases in vivo that may help develop NK cell-dependent cancer therapies.
INTRODUCTION
NK cells are cytotoxic innate lymphoid cells (ILCs), which kill malignant cells Glasner et al., 2012a; Halfteck et al., 2009; Koch et al., 2013; Morvan and Lanier, 2016) , virusinfected cells (Bar-On et al., 2013 Diab et al., 2016 Diab et al., , 2017 Gazit et al., 2006; Glasner et al., 2012b Glasner et al., , 2015a Seidel et al., 2012) , bacteria (Chaushu et al., 2012; Gur et al., 2013a Gur et al., , 2015 , and fungi and also play a role in autoimmunity (Gur et al., , 2011 (Gur et al., , 2013b Wensveen et al., 2015) , allergy (Ghadially et al., 2013) , and graft-versushost disease (Ghadially et al., 2014) . NK cell killing is executed following engagement of activating receptors, which include, among others, the natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46 (Ncr1 in mice). Triggering of NKp46 leads not only to perforin-mediated direct cytotoxicity, but also to secretion of inflammatory cytokines, mainly IFN-g and TNF-a (Morvan and Lanier, 2016) . Several pathogen-derived ligands have been identified for NKp46 such as the influenza, Sendai, and Newcastle disease hemaglutinins (HAs) (Draghi et al., 2007; Gazit et al., 2006; Jarahian et al., 2009 Jarahian et al., , 2011 Mandelboim et al., 2001) , but the identities of its membrane-bound cellular and tumor ligands remain largely unknown. To study NKp46 and Ncr1 activity in vivo, we generated an Ncr1 knockout (KO) mouse in which Ncr1 was replaced by a green fluorescent protein (GFP) reporter (Ncr1 gfp/gfp ) (Gazit et al., 2006) . In the heterozygous Ncr1 +/gfp mice (which are immune competent, as one Ncr1 allele is still present) and in the Ncr1-deficient mice, NK cells develop normally (Gazit et al., 2006; Glasner et al., 2015b; SatohTakayama et al., 2009; Sheppard et al., 2013) . Using these mice, we have demonstrated that Ncr1 is involved in tumor elimination. Specifically, Ncr1 was shown to control the growth of melanoma (Lakshmikanth et al., 2009 ), lymphoma (Halfteck et al., 2009) , carcinoma (Glasner et al., 2012a) , and carcinogeninduced fibrosarcoma (MCA) . However, the mechanisms by which NK cells control tumor development and metastases via Ncr1, in vivo, remain largely unknown. NK cell control of tumor metastases is especially intriguing, as the presence of NK cells within tumors is usually sparse (Delahaye et al., 2011; Desbois et al., 2012) . However, in their absence, increased tumor growth and metastasis were described (Morvan and Lanier, 2016) and the numbers of NK cells in tumors correlates with better prognosis and less likelihood to develop metastases (Delahaye et al., 2011) .
Melanoma is a potentially deadly cutaneous malignancy. Although its prevalence is much lower compared to other skin neoplasms such as basal cell carcinoma and squamous cell carcinoma, it remains the leading cause of death from skin cancers (Guy and Ekwueme, 2011) . Although recent development in the treatment of advanced-stage melanoma yielded substantial improvement in survival (Breunis et al., 2008; Flaherty et al., 2010; Parakh et al., 2017) , disease prevention mainly by avoidance of solar damage is still advocated. Yet in spite of increased use of topical ultraviolet (UV) filters, melanoma incidence is constantly on the rise (Arnold et al., 2014) . Therefore, early diagnosis and rapid surgical removal of the tumors are critical.
Reflectance confocal microscopy (RCM) is a novel, non-invasive imaging technique that permits real-time visualization of cellular components in the skin at a resolution close to that of conventional histology. A detailed description of RCM methodology is available in the STAR Methods. Here we employed RCM imaging in humans and various mouse models to study the role of NKp46 and Ncr1 in controlling tumors and metastases in vivo. We found that triggering of Ncr1 led to IFN-g secretion which in turn led to increased fibronectin1 (FN1) expression in the tumors, affecting their structure and resulting in decreased metastases.
RESULTS

NK Cells Control B16 Tumors and Metastases in an
Ncr1-Dependent Manner NKp46 (Ncr1 in mice) is a major NK cell receptor, whose expression is almost exclusive to NK cells (Delahaye et al., 2011; Desbois et al., 2012; Morvan and Lanier, 2016) . In our previous studies, we observed that although Ncr1 does not affect the development of primary tumors growing in the footpad, it does control the formation of lung metastases (Glasner et al., 2012a) . However, the mechanisms responsible for these effects are unknown. To investigate whether NK cells, via Ncr1, can control primary tumor growth in additional locations (other than the footpad), we inoculated 1 3 10 6 B16F10.9 melanoma (B16) cells subcutaneously (s.c.) into the flank of Ncr1 +/gfp and Ncr1 gfp/gfp mice. In accordance with our previous findings (Glasner et al., 2012a) , no differences were observed in the flank B16 tumor growth rate between the various mice groups ( Figure 1A ). However, similarly to our previous results, almost half the Ncr1 gfp/gfp mice developed spontaneous peritoneal metastases, compared to only about 10% in the immune-competent Ncr1 +/gfp mice (Figure 1B) . We next injected 10-fold decreasing doses of tumor cells directly into the peritoneum to generate experimental peritoneal metastases. However, even in the lowest cell dose, no difference was observed in the Ncr1 ability to control B16 metastases ( Figure 1C , the graph represents mortality rate following metastases formation). This led us to conclude that Ncr1 affects metastases formation irrespective of the primary tumor development, not by restricting tumor growth, but by other mechanisms.
Tumor Properties Are Similar in the Presence or Absence of Ncr1
To test whether the developing tumors change the expression of their unknown Ncr1 ligand following the Ncr1-mediated immune pressure, we isolated primary tumors that had developed in Ncr1 +/gfp and in Ncr1 gfp/gfp mice. As the membrane-bound tumor ligand (or ligands) for Ncr1 and NKp46 are unknown, we stained the tumor cell lines with Ncr1 Ig fusion proteins and observed no differences ( Figure 1D ). Similarly, biochemical properties of the unknown Ncr1 tumor ligand were identical in the presence or absence of Ncr1, being insensitive to neuraminidase (NA) and sensitive to trypsin and proteinase K ( Figure 1E ). A CD107a mobilization assay confirmed that all tumors elicited reduced degranulation in the absence of Ncr1, regardless of the tumor origin ( Figure 1F ). We also observed similar levels of transcripts associated with immune cell populations, such as NK cells ( Figure 1G ) and other immune cells ( Figures 1H-1L Figure 1M ). B16 cells express the IFN-g receptor (IFN-gR) but lack expression of the TNFa receptor (TNFaR) ( Figure 1N Figure 1P ), more metastases were observed in the Ifng À/À and Ncr1 gfp/gfp mice ( Figure 1Q ). These findings suggest that NK cells' ability to control metastases is mediated by IFN-g. Figure S1 shows two human skin lesions that appear similar to the naked eye ( Figures S1A and S1J ). However, RCM evaluation, based on tissue architecture parameters , enabled the accurate classification of the two lesions as nevus (Figures S1A-S1I) and melanoma (Figures S1J-S1R). A detailed description of the analysis is provided in the STAR Methods. We used RCM to evaluate tissue architecture in 11 human melanomas compared to 5 nevi and detected significant differences in all RCM criteria (summarized in Figures S1S-S1Z). Thus, RCM can be used to distinguish between human melanomas and nevi. Only very few works employ RCM in mice (Chernyavskiy et al., 2009; Li et al., 2005; Park et al., 2010) . To test whether mouse melanoma tumors would present RCM features similarly to human melanomas, we performed RCM on B16 tumors and observed that all human melanoma RCM criteria were also Figure 2D ) and nucleated cells inside the papillae ( Figure 2I ). This is likely because the basal layer is very thin in mice and dermal papillae are hard to demonstrate. These findings confirmed RCM as a reliable method to characterize the structural properties of mouse tumors and that B16 melanomas are structurally similar to human melanomas.
Ncr1, via IFN-g Secretion, Modulates the Structural Features of B16 Primary Tumors
To image tumor architecture in vivo, in the absence of Ncr1 and IFN-g, we inoculated Ncr1
, Ncr1 gfp/gfp , and Ifng À/À mice with 1 3 10 6 B16 cells and monitored tumor growth. RCM was performed on tumors of the same volume at two time points: around 1 week and around 2 weeks after tumor inoculation ( Figure 2J ).
RCM analysis revealed significantly worse structural properties for tumors that developed in Ncr1 gfp/gfp and Ifng À/À mice according to four RCM criteria ( Figures 2K-2N ). These criteria have been previously shown, in humans, to correlate with metastatic activity Wisco and Sober, 2012) . As these differences were detected at both time points ( Figures 2K-2N show only the early time point), RCM evaluation was performed around 1 week after tumor inoculation henceforth. No differences were observed in two other RCM features (sheet-like structures and non-homogeneous nests, data not shown).
To corroborate these findings, we evaluated Ncr1 +/gfp and Ncr1 gfp/gfp B16 tumors by conventional histology, using hematoxylin and eosin (H&E) staining. As seen in Figure S2 , and in agreement with the results observed using RCM, worse structural properties were detected for Ncr1 gfp/gfp B16 tumors Figure S2B ; Figure S2C depicts ulceration, quantified in Figure S2D ; Figure S2E depicts muscle invasiveness, quantified in Figure S2F ; and Figure S2G depicts lung metastases, quantified in Figure S2H . Figure S2I shows lowermagnification images of a whole lung lobe for better clarity.)
To test whether IFN-g secretion alters the structural features of the B16 tumors directly, we isolated B16 clones expressing IFN-gR ( Figure Figure 2S ). In the absence of IFN-gR, differences in the four RCM criteria between the groups were significantly diminished or completely abolished ( Figures  2T-2W ). Therefore, we concluded that Ncr1-mediated IFN-g is at least partially responsible for editing the tumor structural properties and that IFN-g acts directly on the tumor cells to modulate tumor architecture.
IFN-g Secretion Upregulates FN1, Resulting in a Structural Organization that Restricts Metastases Formation
To determine the mechanisms by which Ncr1 edits tumor structure via IFN-g, we performed RNA sequencing (RNA-seq) on biological triplicates of IFN-g-treated and untreated B16 cells. Around 7,000 genes were differentially expressed. As expected, the vast majority of the differentially expressed genes coded for proteins participating in antiviral defense, immune response, and MHC regulation (examples are shown in Figure S3A ). As we observed that Ncr1 affects tumor architecture, we searched for changes in the expression of structural genes, cell adhesion, and cellular matrix proteins ( Figure S3A ). Among the enriched structural genes, the expression of the extracellular matrix protein fibronectin1 (FN1) was increased by 24-fold (Figures 3A, S3A, and S3B). This finding was validated in the presence or absence of IFN-g, using western blotting (WB) ( Figure 3B ) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) ( Figure 3C ). To demonstrate the effect FN1 has on tumor architecture, we initially tried to overexpress FN1 in B16 and other tumors, using various methods without success, probably due to its high molecular weight ($440 kDa). Instead, we knocked down (KD) FN1 in B16 cells using five independent short hairpin RNA (shRNAs). Figures 3D (WB) and 3E (qRT-PCR) represent one KD line. Figure S4A shows all control and KD lines generated. We then inoculated Ncr1
gfp/gfp , and Ifng À/À mice with the control and FN1 KD B16 cells and monitored tumor growth. As before, all tumors developed with comparable kinetics (Figure 3F ). Mice inoculated with FN1 KD melanomas exhibited increased metastasis ( Figure 3G 
Ncr1 Edits Lewis Lung Carcinoma Tumors via IFN-g and FN1 and Prevents Metastases
To demonstrate that the Ncr1-dependent structural editing of tumors is not restricted to a particular cell line or tumor type, we next used the Lewis lung carcinoma line D122 (Eisenbach et al., 1983a; Glasner et al., 2012a) . D122 tumors expressed IFN-gR ( Figure 4A ) and the unknown Ncr1 ligand ( Figure 4B ). D122 cells elicited significantly higher IFN-g and TNFa secretion by NK cells derived from Ncr1 +/gfp than Ncr1 gfp/gfp mice (Figure S5A) . The IFN-g secretion was abolished in the presence of an Ncr1 blocking antibody ( Figure S5B Figure S5C showing all KD and control lines generated) and inoculated Ncr1
gfp/gfp , and Ifng À/À mice with a control or FN1 KD D122 tumors.
As the use of RCM imaging is restricted to skin neoplasms, the D122 tumors were inspected using conventional histopathology, which was performed on tumors of the same developmental stage and volume ( Figure 4G ). Worse structural properties such as ulceration ( Figures 4H-4J ), muscle invasiveness ( Figures  4K-4M ), and metastasis ( Figures 4N-4P) were observed in the tumors grown in Ncr1-or in IFN-g-deficient mice, as well as in all FN1 KD tumors, irrespective of mouse genotype. In line with these observations, FN1 expression was significantly reduced in vivo in the Ncr1 gfp/gfp and Ifng À/À tumors and in all FN1 KD D122 tumors ( Figure 4Q , one representative FN1 KD line is shown).
IFN-g Treatment and Ncr1 Overexpression Prevent Metastases
Based on all of the above, we concluded that IFN-g treatment should impair metastasis via FN1 induction. To test this, we injected B16-bearing mice with IFN-g. Reduced metastases formation was observed in all IFN-g-treated mice ( Figure 5A ), and RCM properties were significantly improved upon IFN-g treatment, regardless of the mice genotype ( Figures 5B-5E ). We also concluded that overexpressing Ncr1 in NK cells may offer a therapeutic opportunity to suppress metastasis. To test this, we used a transgenic mouse that we have generated (Glasner et al., 2017) Figure 5F ). However, fewer metastases developed in Ncr1 cre Ncr1 OE mice, compared to littermate controls ( Figure 5G ). RCM features were better in Ncr1 cre Ncr1 OE mice as well ( Figures 5H-5K ), paralleled by higher levels of Ncr1, IFN-g, and FN1 ( Figures 5L-5N ). Throughout the course of this study, we evaluated tumor volume and metastases in several independent experiments and in various different mouse groups. To account for differences in experimental settings and make an accurate comparison between all mice groups, we performed an experiment combining all mice genotypes. We evaluated B16 tumor growth kinetics ( Figure S6A ) and B16 metastatic formation ( Figure S6B ), as well as D122 tumor growth kinetics ( Figure S6C ) and metastatic formation ( Figure S6D ) and observed that in all cases Ncr1 did not affect primary tumor growth. In contrast, metastases formation was Ncr1 dependent as in its absence increased metastases were detected, while upon its overexpression metastases formation decreased (Figures S6B and S6D ).
NK cells and T cells are the main source of IFN-g (Desbois et al., 2012; Fauriat et al., 2010; Garber, 2016; Morvan and Lanier, 2016 inoculation and every third day after until the time of RCM, the control mice were injected with either an anti-NK1.1-depleting antibody (to deplete NK cells) ( Figure S6E ) or an anti-CD3-depleting antibody (to deplete T cells) ( Figure S6F ). Depletion was verified by flow cytometry at different time points along the experiment. Additionally, a control group was administered an anti-IFN-g blocking antibody. Mice were also treated with recombinant IFN-g or left untreated ( Figure 6 ). Tumors in all mice groups developed at a comparable rate and reached a similar final volume ( Figure 6A ). Increased metastases were observed in NK1.1-but not in CD3-depleted mice ( Figure 6B ). Moreover, increased metastases formation was observed also when blocking IFN-g antibodies were used or in Ifng À/À mice.
Recombinant IFN-g administration reduced metastases in all groups ( Figure 6B ). Likewise, in Ncr1 cre Ncr1 OE mice, metastases were significantly reduced ( Figure 6B ).
We next performed RCM evaluation ( Figures 6C-6F ). Worse RCM scores were recorded in the absence of Ncr1 (EMT) profile and to the expression of various EMT-associated transcription factors (TFs). To investigate how FN1 contributes to the prevention of metastases, we inoculated Ncr1 +/gfp and Ncr1 gfp/gfp mice with B16 and D122 tumors and assessed the level of various EMT associated TFs at different time points following tumor inoculation. Figure S7 represents data obtained from tumors harvested at day 7 (day of RCM) after tumor inoculation. We found increased expression of Keratin ( Figure S7A (Figures S7F-S7J ). We thus concluded that an association to a reduced EMT profile may provide a partial mechanistic explanation as to the effect by which Ncr1-mediated IFN-g secretion and FN1 induction in tumors prevents metastases in our model.
To extend our findings to humans, we initially stained various primary melanoma lines obtained from patients for the expression of IFN-gR ( Figure 7A ) and the unknown human NKp46 tumor ligand ( Figure 7B ) and observed expression of both in all tested tumors ( Figures 7A and 7B) .
We next analyzed datasets from patients of various cancers, including melanoma and carcinoma. Our analysis demonstrated that high expression of each of the tested genes alone: Ncr1 ( Figure 7C ), IFN-g ( Figure 7D ), IFN-gR ( Figure 7E ), and FN1 (Figure 7F ) was associated with statistically insignificant (Ncr1, IFN-g IFN-gR, Figures 7C-7E ) or statistically significant but small (FN1, Figure 7F ) increase in survival rates. However, the combined See also Figure S6 .
expression of all genes in primary tumors correlated with significantly improved recurrence-free survival ( Figures 7G and 7H ).
DISCUSSION
We Glasner et al., 2012a; Halfteck et al., 2009 ) and others (Lakshmikanth et al., 2009 ) have demonstrated that NK cells, through the killer receptor NKp46, eliminate various tumor metastases. However, the mechanisms by which NKp46 and Ncr1, in mice, influence metastasis in vivo remain unknown. Here, we demonstrated that Ncr1 edits the structure of developing tumors at the level of tissue organization and that this effect is mediated by the IFN-g-FN1 pathway. We further demonstrated that after this structural editing, metastases formation is restricted. We have previously demonstrated that Ncr1 control of various mouse tumors is mediated by direct killing rather than cytokine secretion (Glasner et al., 2012a) . However, cytokine measurement in the previous study was performed after 48 and 76 hr of incubation with the targets (in contrast to 12 hr here), which may have been inappropriate, as IFN-g and TNFa, the main NK cell cytokines, are secreted very rapidly and have a very short half-life (Fauriat et al., 2010) . By using RCM in vivo, which as opposed to conventional histological examination, enables in situ visualization of tumor architecture, we were able to determine that the killer receptor NKp46/Ncr1 affects melanoma tumors by modifying the tumors' structural properties. This effect was achieved through the secretion of IFN-g and modulating tumor organization by upregulating the extracellular matrix protein FN1. Pellacani et al. (2007) used RCM in humans and defined the aggressiveness of the tumors and their probability to metastasize. We observed that the B16 melanoma model is very similar to human melanoma, sharing similar RCM structural properties. In our RCM evaluation, we found the features of epidermal disarray, epidermal cellular atypia, dermal-epidermal junction cellular atypia, and dermal epidermal junction cerebriform like cell-clusters (nests) to be much more pronounced in primary tumors developed in the Ncr1 gfp/gfp mice than in those developed in the Ncr1
mice. These criteria are particularly important as they are associated with melanomas thicker than 1 mm in depth (melanoma thickness is positively correlated to metastatic activity) (Wisco and Sober, 2012) . This means that in the absence of Ncr1, tumors of the same developmental stage and volume feature more aggressive properties. Indeed, we observed significantly higher spontaneous metastasis in the absence of Ncr1. To demonstrate that Ncr1-mediated induction of IFN-g is the main element playing a role in these effects, we employed several different methods throughout our study. First, we used B16 tumors expressing very low levels of IFN-gR or an IFN-g blocking antibody and observed significant worse metastasis and structural properties. Next, when depleting NK cells, but not T cells, we also observed worse metastases formation and worse structures in the developing tumors. Finally, administration of recombinant IFN-g reversed these effects. The results presented here, demonstrating that Ncr1 inhibits the aggressiveness of the developing tumors via IFN-g, are particularly important as triggering of Ncr1 may provide the only source of IFN-g. CD8 + T cells are often inhibited at the sites of tumors, due to MHC class I downregulation. For example, in about 67% of human melanomas, MHC class I expression is downregulated via various mechanisms (Degenhardt et al., 2010) and thus the secretion of IFN-g from CTLs is prevented. Furthermore, many human melanomas do not express NKG2D ligands (Fuertes et al., 2008) and therefore NKG2D, one of the other major NK cell receptors involved in IFN-g secretion, cannot be activated. Ncr1 is also expressed by ILCs, although its function on these cells was shown to be redundant (Rankin et al., 2016; Satoh-Takayama et al., 2009) . We demonstrated that editing of tumor architecture by Ncr1 is not restricted to a particular cell line or tumor type, as we showed that Ncr1 affects the structural properties and metastasis of D122 in an IFN-g-and FN1-dependent manner. Furthermore, we were able to generalize our findings to a wide range of human tumors, by analyzing human patients' data files using the NIH TCGA database. Importantly, post hoc analysis of TCGA data has many caveats and these data should be considered as hypothesis generating.
Most of the above-mentioned activities of Ncr1 were demonstrated via the Ncr1 gfp/gfp mice (Gazit et al., 2006) . To determine the therapeutic potential of our findings, we used a transgenic mouse in which Ncr1 is overexpressed in NK cells (Ncr1 cre Ncr1 OE ) (Glasner et al., 2017) . In these transgenic mice, tumor architecture assessed by RCM imaging was found to be better than in the non-transgenic littermates and led to fewer metastases formation via the same IFN-g-FN1 pathway. These observations suggest that overexpression of NKp46 in NK cells may provide an important perspective for NK cell immunotherapy. We demonstrated here that Ncr1 impedes metastases via editing of primary tumors in an IFN-g-FN1-dependent manner. However, FN1 involvement in tumor development is complex. FN1 is upregulated in various cancers, including mouse and human metastatic melanomas (Clark et al., 2000; Kudo-Saito et al., 2009; Sengupta et al., 2010) . FN1 is also an important mesenchymal gene associated with a reduction in E-cadherin levels and increase in N-CAD, Vimentin, and other TFs associated with EMT and metastasis (Lamouille et al., 2014) . On the other hand, FN1 was found to inhibit tumor growth and metastasis (Liu et al., 2008; Yi and Ruoslahti, 2001 ). Failure to deposit stromal FN1 by the tumors was correlated to higher migration, invasion, and metastatic activity (Liu et al., 2008) . Reduced FN1 levels were reported at the peripheral margins of invading tumors and FN1 silencing in some tumors enhanced tumor growth as well as promoted lung metastases (Liu et al., 2008 isolated from patients, compared to the higher metastatic ones, in an immunodeficient mouse xenotransplant metastasis model (Xu et al., 2008) . Clearly, FN1 is a prominent tumor marker important for many tumor processes. However, FN1 presence in the tumors is dynamic, and its expression at certain loci or time points in tumor development may direct metastatic activity. Possibly, the association of FN1 expression in tumors with an increased EMT profile documents the result of a complex interaction between the immune system and the tumor.
In summary, our observations indicate that even in the early pre-metastatic stage, the tumor ''prepares'' itself to disseminate and that even at this stage NK cells, via Ncr1-mediated secretion of IFN-g, attempt to counter these morphological changes. The finding that Ncr1, through IFN-g and FN1, is involved in modifying tumor organization and consequently restricting metastasis represents a potential avenue for treatment. This paradigm may pave the way to anti-cancer treatment options and to the development of drugs specifically aimed at targeting tumor architecture.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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The authors declare no competing interests. education is normal (Gazit et al., 2006; Glasner et al., 2015b; Satoh-Takayama et al., 2009; Sheppard et al., 2013) IFN-g À/À and TNFa À/À mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Ncr1 cre Ncr1 OE mice were generated by crossing Ncr1 cre (Eckelhart et al., 2011) and Ncr1 Rosa Stop mice (Glasner et al., 2017) . All mice were housed under SPF conditions, normal light/dark cycles and 22 +/À 2 C. All experiments were performed in a specific pathogen free unit of the Hebrew University Medical School (Ein-Kerem, Jerusalem) in accordance with the guidelines of the ethics committee. Mice of different genotypes (or littermates when relevant) were allocated randomly to the different experimental groups in each experiment. Peritoneal tumor growth was assessed by injecting 10-fold decreasing dose of B16 cells into the peritoneal cavity of Ncr1 +/gfp and Ncr1 gfp/gfp mice. The mice were monitored daily, and sacrificed at any indication of illness such as bristled fur, difficult breathing, tremor or any other sign of disease. The sacrificed mice chest and peritoneal cavities were explored post-mortem, and the presence of tumors was visually verified. Any surviving mice were sacrificed at day 120 post tumor inoculation, their chest cavities were explored and the absence of metastases was verified by visual inspection. For RCM evaluation, histopathological analysis and spontaneous metastases assessment, B16 or D122 cells were subcutaneously (s.c.) injected into the flank and tumors were monitored daily. RCM evaluation and histopathological analysis were always conducted in a blinded manner, where the evaluating physician inspected randomly-numbered coded image files or numbered H&E stained slides with no indication of the animal's genotype. In all experiments, by the time tumors reached a maximal volume of 1000mm 3 , all mice were sacrificed and the presence of metastases in the peritoneum and chest cavity was assessed visually. No differences were observed between the various mice groups in their general health at baseline.
Cells
Male B16F10.9 (B16) cells and D122 Lewis Lung Carcinoma (D122) were kindly provided by Prof. Eisenbach (The Weizmann Institute of Science, Rehovot, Israel). Cells were authenticated. Cells were grown in DMEM supplemented with 1% L-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, 1% pen strep and 5% FCS. Cells were grown in 37 C, 5% CO2. To obtain cell lines from the B16 tumors of Ncr1 +/gfp and Ncr1 gfp/gfp mice, tissue samples were treated with trypsin, washed and placed in culture.
Two days later, tissues were removed and cells were grown in supplemented DMEM. All cells were stained for the expression of Ncr1 ligand within one week in culture at most. PK treatment included 20 min incubation of the cells with 10ml PK (20 mg/ml); Sigma-Aldrich, Rehovot, Israel) in 37 C, 5% CO2.
METHOD DETAILS
Fusion proteins, antibodies, and flow cytometry The Ncr1 Ig and NKp46 Ig fusion proteins were generated by PCR amplification of mouse and human cDNA, and cloned in frame with human IgG. The resulting constructs were transduced into HEK293T cells. Treatment of fusion proteins with NA included incubation with 10ug NA (Mercury, Israel) for 2 hours at 37 C. The integrity of the treated fusion proteins was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel analysis. The staining of all cell lines by fusion proteins was visualized using an Alexa FluorÒ 647 conjugated Goat Anti-Human IgG, F(ab') 2 (JacksonImmunoResearch Laboratories, West Grove, PA). To assess IFN-gR, biotin anti-mouse CD119 (IFN-gR a chain), (BioLegend) was used. To asses TNFaR, purified anti-mouse TNFa Antibody (BioLegend) was used. IFN-gR and TNFaR staining was visualized using Alexa FluorÒ 647 Streptavidin, or Alexa FluorÒ 647 conjugated Goat Anti-Mouse IgG (H+L) secondary antibodies (JacksonImmunoResearch Laboratories, West Grove, PA), respectively. mNcr1.15was used as a blocking anti-Ncr1 antibody. Polyclonal FN1 antibodies (Abcam) were used for WB and IF staining. For the treatment of B16 and D122 cells with IFN-g, cells 1
x 10 6 cells were seeded in triplicates and supplemented with recombinant mouse IFN-g (carrier free) (BioLegend) containing medium (50mg /ml) for 24 hours. For in vivo depletion of NK1.1 expressing cells, mice were injected i.p every third day with 25mg of InVivoMAb anti mouse NK1.1, clone PK136 (Bio X Cell). For in vivo depletion of CD3 expressing cells, mice were injected every third day with 200mg of InVivoMAb anti mouse CD3ε, clone 145-2C11 (Bio X Cell). For in vivo blocking of IFN-g, mice were injected i.p. every third day with 200mg of InVivoMAb anti-mouse IFN-g, clone XMG1.2 (Bio X Cell). For recombinant IFN-g treatment, mice were injected every third day with 100mg of IFN-g (carrier free) (BioLegend).
CD107a degranulation and cytokine secretion assays Mice were injected intraperitoneally (i.p.) with 200mg Poly I:C (Sigma Aldrich Israel) and PBLs were harvested 18 hours later. NK cells were isolated using the EasySepT mouse NK cell enrichment kit and co-incubated at 37 C at the indicated ratios, with the target cells in the presence of an APC conjugated anti-mouse CD107a (LAMP-1) (Biotest (121614) for two hours and CD107a levels on the GFP-positive NK cells were determined by flow cytometry. To assess IFN-g and TNFa secretion, NK cells were isolated from Poly I:C activated PBLs using the EasySepTM mouse NK cell enrichment kit and incubated with B16 cells at 37 C and 5% CO2. Then, supernatants were collected and cytokines levels were measured using standard ELISA.
Evaluation by RCM
In vivo RCM was performed using a reflectance confocal microscope (Vivascope 1500, Caliber I.D. Inc., Rochester, NY, USA). The system uses an 830-nm wavelength diode laser. The laser beam is directed by a dichromatic mirror (beam splitter) toward a pair of mirrors that perform horizontal scanning of the selected skin area. The laser beam then passes through the microscope objective lens and enters the skin where it can encounter tissue structures of various reflective properties. Next, backscattered light from the tissue re-enters the objective lens and the dichromatic mirror that focuses it onto a gating pinhole. A photomultiplier detector measures the light that enters via the pinhole and produces optical images. The system provides high optical resolution (horizontal axis 2.0mm; vertical axis 5.0mm) to a penetration depth of about 250mm.
Ultrasound gel was used as an immersion medium (refractive index 1.33). A set of sequential horizontal RCM optical sections (each 500um x 500um in area) was acquired at 1.0um intervals from the corneal skin layer (skin surface) to the hypodermis (fatty layer under the skin). For each tumor, we obtained at least 20 images, optically sectioning through the corneal layer, granular and spinous layers, basal layer / epidermal-dermal junction, upper dermis, lower dermis and hypodermis. RCM features of melanoma were recognized and quantified by either counting the number of times they appear in a 1mm 2 area or by grading them on a 1-10 scale (1 = least aggressive to 10 = most aggressive). Evaluator of the above features was blinded to the genotype of the mice and the tumors.
